MedReleaf signs supplier agreement with Shoppers Drug Mart
MARKHAM, ON, Dec. 21, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company") has announced today that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.
Subject to Health Canada's approval of Shoppers Drug Mart's application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with MedReleaf branded medical cannabis products. It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.
"From inception, MedReleaf has been focused on setting the standard for patient care in our industry and producing consistent, high quality medicine," said Neil Closner, CEO of MedReleaf. "With this agreement, we look forward to making our award-winning strains available as the trusted provider of premium cannabis-based pharmaceutical products to the largest pharmacy retailer in Canada."
About MedReleaf Corp.
MedReleaf sets The Medical Grade Standard™ for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified cannabis producer in North America, MedReleaf is an R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and carefully cultivated in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.
For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf.
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, which can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. The forward-looking information contained in this press release are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events which management believes to be reasonable in the circumstances, including expectations and assumptions regarding the regulatory environment in Canada. Forward-looking information are subject to known and unknown risks and uncertainties, including risks and uncertainties which could cause actual events or results to differ materially from those described in any forward‑looking information, including risks and uncertainties relating to general economic conditions, changes in the regulatory and legal environments relating to cannabis, competition, counterparty risk, as well as those risks and uncertainties and other cautionary statements contained in MedReleaf's Annual Information Form dated June 27, 2017, which is available electronically at www.sedar.com. Any forward-looking information contained herein speaks only as of the date on which it is given and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward‑looking information, whether as a result of new information, future events or otherwise.
SOURCE MedReleaf Corp.
Dennis Fong, Investor Relations, [email protected], 416-283-9930
Share this article